Year: 2024

Takeda_Red_Logo_2021-2

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to...

logo-54

Global and China Automotive Integrated Die Casting Industry Report 2024: Technical Barriers to Non-heat Treatment Have Been Broken down and Chinese Players Acquire Ever More Patents – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Automotive Integrated Die Casting Industry Report, 2024" report has been added to ResearchAndMarkets.com's offering. Integrated Die Casting Research:...

logo-53

Australia Rail Signalling Industry Research 2024-2030: Increased Focus on Modernisation and Expansion of Metro and Rail Network Bolsters Expansion – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Australia Rail Signalling Market 2024-2030 Size, Trends, Segmentation, Revenue, Outlook, Companies, Share, Growth, Analysis, Value, Industry & Forecast:...